• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Congenital Cytomegalovirus

Congenital Cytomegalovirus - 25 Studies Found

Completed : Diagnosis of Congenital CMV Infection in Neonates Who Failed Newborn Hearing Screening
: Congenital Cytomegalovirus Infection
: 2014-04-28
: Other: CMV PCR Other Name: CMV PCR results are communicated to the relevant clinicians in real time.
Completed : Assesment of Olfactory Disorders and Performance of a New Olfactory Test in Children With Congenital CMV
: Congenital Cytomegalovirus Infection
: 2016-05-23
: Other: olfactory tests, otoacoustic emissions (OAE) Two series of olfactory tests will be performed : 1)
Terminated : Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial
:
  • Congenital Cytomegalovirus Infection
  • Sensorineural Hearing Loss
    : 2012-07-13
    : Drug: Valganciclovir Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two
Completed : Congenital Cytomegalovirus: Efficacy of Antiviral Treatment
:
  • Congenital Cytomegalovirus Infection
  • Sensorineural Hearing Loss
    : 2013-12-04
    : Drug: Valganciclovir Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two
Completed : A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
:
  • Congenital Cytomegalovirus Infection
  • Maternal Cytomegalovirus I
    : 2011-06-15
    : Drug: CMV hyperimmune globulin The study's active drug is Cytogam® which is an immunoglobulin G (Ig
Not yet recruiting : Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance
: Congenital Cytomegalovirus (CMV)
: 2015-11-05
: Drug: Valganciclovir Oral valganciclovir (Rovalcyte 50 mg/ml, powder for oral suspension) at a dose of 1
Completed : Congenital CMV and Hearing Loss in Children up to 4 Years of Age: Treating With Valganciclovir Therapy
:
  • Congenital Cytomegalovirus
  • Hearing Loss

: 2012-07-20
:
  • Drug: Valcyte (Valganciclovir hydrochloride) Powder for oral solution

Completed : A Cross-sectional Study of Congenital Cytomegalovirus Infection in Newborns in China
: Congenital Cytomegalovirus Infection
: 2016-03-05
Completed : Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy
: Congenital Cytomegalovirus Infection
: 2015-01-18
:
  • Drug: Valacyclovir
  • Drug: Placebo

Withdrawn : Safety, Tolerability, and Immunogenicity of a Cytomegalovirus DNA Vaccine
: Congenital Cytomegalovirus Infection
: 2015-10-16
: Drug: CyMVectin CyMVectin will be delivered by unilateral intramuscular (IM) injection at Day 0, Day 28(
Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.